Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/127793RESPIRATORY SYNCYTIAL VIRUS-SPECIFIC BINDING MOLECULE
WO 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/138018 Applicant TRINOMAB BIOTECH CO., LTD. Inventor LIAO, Huaxin
The present disclosure relates to a respiratory syncytial virus (RSV)-specific binding molecule and an application thereof. Further provided in the present disclosure are a method for preparing the molecule, and an application of the molecule in the preparation of a product that specifically binds to an RSV surface glycoprotein fusion protein and in the preparation of an RSV vaccine, and other such aspects.
2.WO/2022/132904HUMAN MONOCLONAL ANTIBODIES TARGETING SARS-COV-2
WO 23.06.2022
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2021/063525 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor TAN, Joshua Hoong Yu
Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and bi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV and/or a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and bi-specific antibodies.
3.WO/2022/132887HUMAN MONOCLONAL ANTIBODIES TARGETING THE SARS-COV-2 SPIKE PROTEIN
WO 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/063493 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor GOLLIHAR, Jimmy, Dale
Provided herein are antibodies and antibody fragments that bind to SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein-targeting antibody.
4.WO/2022/127739ANTIGEN-BINDING PROTEIN SPECIFICALLY BINDING TO SARS-COV-2
WO 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/137499 Applicant JECHO BIOPHARMACEUTICALS CO., LTD Inventor ZHU, Jianwei
Provided is an isolated antigen-binding protein specifically binding to SARS-CoV-2, a method for preparing the antigen-binding protein, and the pharmaceutical use thereof. The antigen-binding protein comprises at least one CDR in a light chain variable region VL, wherein the CDR comprises an amino acid sequence as shown in SEQ ID NO: 95.
5.WO/2022/122993FORMULATION FOR MULTI-PURPOSE APPLICATION
WO 16.06.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/EP2021/085139 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor BLECH, Michaela
The present invention relates in general to the formulation of antibodies and antigen-bind-ing fragments thereof. In order to address a need for formulations for new antibodies that are able to be administered by different routes as well as in low and high dosage a formulation comprising an antibody or antigen-binding fragment thereof is provided, as well as uses of the formulation and methods involving the formulation.
6.WO/2022/125378COMBINATION THERAPY
WO 16.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/061697 Applicant VIIV HEALTHCARE COMPANY Inventor HONG, Zhi
The present invention relates to a combination of cabotegravir or a pharmaceutically acceptable salt thereof and a gp120 binding protein. The present invention also provides a method of treatment human immunodeficiency virus (HIV) with the co-administration of a therapeutically effective amount of cabotegravir or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a gp120 binding protein.
7.WO/2022/125517ANTIBODIES AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION
WO 16.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/062160 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, Davide
The present disclosure provides antibodies that neutralize infection of influenza A virus. The disclosure also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies. In addition, the disclosure provides the use of the antibodies of the disclosure in prophylaxis and treatment influenza A infection.
8.WO/2022/122788MULTISPECIFIC ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
WO 16.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2021/084708 Applicant INSTITUTE FOR RESEARCH IN BIOMEDICINE Inventor VARANI, Luca
The present invention provides multispecific antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in particular, multispecific antibodies binding to distinct epitopes of the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. The present invention also provides the use of such antibodies, e.g. for prophylaxis or treatment of coronavirus disease-2019 (COVID-19) or for (in-vitro) diagnostic purposes.
9.WO/2022/125789COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING VIRAL INFECTIONS
WO 16.06.2022
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/US2021/062632 Applicant YALE UNIVERSITY Inventor PYLE, Anna, Marie
The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5'-triphosphate or a 5'-diphosphate.
10.WO/2022/122704ANTIBODIES BINDING TO F-PROTEIN OF METAPNEUMOVIRUS AND USES THEREOF
WO 16.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2021/084520 Applicant HUMABS BIOMED SA Inventor BENIGNI, Fabio
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the F-protein (fusion protein) of metapneumovirus (MPV). The antibodies, and antigen binding fragments thereof, neutralize infection of MPV. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in methods for detecting and checking an MPV antigen as well as in the diagnosis, treatment and prevention of MPV infection.